Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Sociedade Portuguesa de Pneumologia
2016
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876482355868205056 |
|---|---|
| author | J.M. Pereira |
| author_facet | J.M. Pereira |
| contents | Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? J.M. Pereira A. Azevedo C. Basílio C. Sousa-Dias P. Mergulhão J.A. Paiva Medicina Outcome Biomarkers Proadrenomedullin Critically ill patients Severe community acquired pneumonia Background: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). Materials and methods: Prospective, single-center, cohort study of 19 SCAP patients admitted to the ICU within 12 h after the first antibiotic dose. Results: At ICU admission median MR-proADM was 3.58 nmol/l (IQR: 2.83---10.00). No significant association was found between its serum levels at admission and severity assessed by SAPS II (Spearman’s correlation = 0.24, p = 0.31) or SOFA score (SOFA < 10: <3.45 nmol/l vs. SOFA ≥ 10: 3.90 nmol/l, p = 0.74). Hospital and one-year mortality were 26% and 32%, respectively. No significant difference in median MR-proADM serum levels was found between survivors and non-survivors and its accuracy to predict hospital mortality was bad (aROC 0.53). After 48 h of antibiotic therapy, MR-proADM decreased in all but 5 patients (median −20%; IQR −56% to +0.1%). Its kinetics measured by the percent change from baseline was a good predictor of clinical response (aROC 0.80). The best discrimination was achieved by classifying patients according to whether MR-proADM decreased or not within 48 h. No decrease in MR-proADM serum levels significantly increased the chances of dying independently of general severity (SAPS II-adjusted OR 174; 95% CI 2---15,422; p = 0.024). Conclusions: In SCAP patients, a decrease in MR-proADM serum levels in the first 48 h after ICU admission was a good predictor of clinical response and better outcome. © 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espa˜na, S.L.U. 2016 artículo científico 0873-2159 https://www.redalyc.org/articulo.oa?id=169749132002 en http://www.redalyc.org/revista.oa?id=1697 Revista Portuguesa de Pneumología application/pdf Sociedade Portuguesa de Pneumologia Revista Portuguesa de Pneumología (Portugal) Num.6 Vol.22 |
| format | Artículo científico |
| id | redalyc_169749132002 |
| institution | Redalyc |
| language | en |
| publishDate | 2016 |
| publisher | Sociedade Portuguesa de Pneumologia |
| spellingShingle | Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? J.M. Pereira Medicina Outcome Biomarkers Proadrenomedullin Critically ill patients Severe community acquired pneumonia Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? J.M. Pereira A. Azevedo C. Basílio C. Sousa-Dias P. Mergulhão J.A. Paiva Medicina Outcome Biomarkers Proadrenomedullin Critically ill patients Severe community acquired pneumonia Background: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). Materials and methods: Prospective, single-center, cohort study of 19 SCAP patients admitted to the ICU within 12 h after the first antibiotic dose. Results: At ICU admission median MR-proADM was 3.58 nmol/l (IQR: 2.83---10.00). No significant association was found between its serum levels at admission and severity assessed by SAPS II (Spearman’s correlation = 0.24, p = 0.31) or SOFA score (SOFA < 10: <3.45 nmol/l vs. SOFA ≥ 10: 3.90 nmol/l, p = 0.74). Hospital and one-year mortality were 26% and 32%, respectively. No significant difference in median MR-proADM serum levels was found between survivors and non-survivors and its accuracy to predict hospital mortality was bad (aROC 0.53). After 48 h of antibiotic therapy, MR-proADM decreased in all but 5 patients (median −20%; IQR −56% to +0.1%). Its kinetics measured by the percent change from baseline was a good predictor of clinical response (aROC 0.80). The best discrimination was achieved by classifying patients according to whether MR-proADM decreased or not within 48 h. No decrease in MR-proADM serum levels significantly increased the chances of dying independently of general severity (SAPS II-adjusted OR 174; 95% CI 2---15,422; p = 0.024). Conclusions: In SCAP patients, a decrease in MR-proADM serum levels in the first 48 h after ICU admission was a good predictor of clinical response and better outcome. © 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espa˜na, S.L.U. 2016 artículo científico 0873-2159 https://www.redalyc.org/articulo.oa?id=169749132002 en http://www.redalyc.org/revista.oa?id=1697 Revista Portuguesa de Pneumología application/pdf Sociedade Portuguesa de Pneumologia Revista Portuguesa de Pneumología (Portugal) Num.6 Vol.22 |
| title | Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? |
| topic | Medicina Outcome Biomarkers Proadrenomedullin Critically ill patients Severe community acquired pneumonia |
| url | https://www.redalyc.org/articulo.oa?id=169749132002 |